Intervention to improve medication adherence in children with leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to identify and address barriers to medication adherence among families of children diagnosed with acute lymphoblastic leukemia (ALL). The MedSupport intervention is a multilevel approach targeting organizational, healthcare team, and caregiver levels to enhance adherence to the oral chemotherapy drug 6-mercaptopurine (6-MP). By comparing adherence rates between families receiving the MedSupport intervention and those receiving usual care, the study seeks to understand the experiences of families managing their child's chemotherapy at home. The trial also explores potential mediators and moderators of intervention efficacy through statistical modeling.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Parent of a child diagnosed with acute lymphoblastic leukemia (ALL)
* Child patient age 365 days to \< 19 years at time of study entry.
* Parent's child patient's therapy must include 6-mercaptopurine (6-MP) administered orally or by nasogastric (NG) tube.
* Verbal fluency in English, or Spanish
* Parent has a smartphone or computer access with an Internet connection.
* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

* Parent is unwilling or unable to follow protocol requirements.

Where it's running

• Roswell Park Cancer Institute
  Buffalo, New York, United States Recruiting

Study contacts

• Principal investigator: Kara M Kelly — Roswell Park Cancer Institute

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies

  This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.

  Recruiting at 7 sites Versailles Hospital · Amiens and 22 other locations · NCT07684131

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

• TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults

  This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07572136

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.